•
Dec 31, 2019

OrthoPediatrics Q4 2019 Earnings Report

OrthoPediatrics experienced revenue growth and strategic advancements.

Key Takeaways

OrthoPediatrics Corp. reported a strong fourth quarter and full year 2019, marked by a 30.1% increase in Q4 revenue to $19.0 million and a 26.0% increase in full-year revenue to $72.6 million. The company launched new products, expanded its sales organization, and strengthened its cash position through a follow-on offering.

Total revenue increased to $19.0 million, up 30.1% from Q4 2018.

Trauma and Deformity revenue grew by 34%, Scoliosis by 21%, and Sports Medicine/Other by 18%.

Launched PediFoot Deformity Correction System and QuickPackâ„¢ bone graft substitute.

Strengthened cash position with $60 million in net proceeds from follow-on offering.

Total Revenue
$19M
Previous year: $14.6M
+30.1%
EPS
-$0.29
Previous year: -$0.19
+52.6%
Gross Profit Margin
76.2%
Previous year: 72.2%
+5.5%
Gross Profit
$14.5M
Cash and Equivalents
$72M
Free Cash Flow
-$8.21M
Total Assets
$195M

OrthoPediatrics

OrthoPediatrics

OrthoPediatrics Revenue by Segment

OrthoPediatrics Revenue by Geographic Location

Forward Guidance

OrthoPediatrics provided full year 2020 revenue guidance of growth in the range of 22%-24% and investment in consignment sets to be in a range of $19-$21 million.

Positive Outlook

  • Revenue growth in a range of 22% to 24% year-over-year
  • Investing $19-$21 million in consigned sets for 2020
  • Focus on deploying capital-efficient systems
  • Realizing the revenue impact from the full roll-out of recent product launches
  • Commitment to pediatric-specific surgical solutions

Revenue & Expenses

Visualization of income flow from segment revenue to net income